An Open-label, Positron Emission Tomography (PET) Study to Evaluate Brain Receptor Occupancy, Safety, Tolerability, and Pharmacokinetics After Single Oral Doses of ITI-333 in Healthy Subjects
Latest Information Update: 25 Feb 2025
At a glance
- Drugs ITI-333 (Primary)
- Indications Anxiety disorders; Depressive disorders; Mood disorders; Pain; Substance-related disorders
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Intra-Cellular Therapies
- 19 Feb 2025 Status changed from recruiting to completed.
- 10 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Aug 2023.
- 10 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2023.